Managing type 2 diabetes can be a daily challenge. Many people spend years trying different medications, changing their diets, exercising more, and monitoring their blood sugar levels, yet still struggle to keep their condition under control.
For these individuals, a new combination treatment reported in leading medical journals may offer fresh hope.
Researchers recently presented results from three major clinical studies examining a once-weekly combination of cagrilintide and semaglutide. The studies were published online in The Lancet Diabetes & Endocrinology and The Lancet and were also presented at the 2025 American Diabetes Association meeting in New Orleans.
Type 2 diabetes affects hundreds of millions of people worldwide. The condition develops when the body’s cells stop responding properly to insulin, the hormone that helps move sugar from the bloodstream into cells for energy.
As blood sugar levels remain elevated, damage slowly occurs throughout the body. This damage can affect the heart, kidneys, eyes, nerves, and blood vessels.
For decades, doctors have relied on a variety of medications to lower blood sugar. Metformin is often the first treatment prescribed. Some patients also take SGLT2 inhibitors or insulin. More recently, drugs such as semaglutide have become increasingly popular because they help lower blood sugar while also promoting weight loss.
Semaglutide works by copying the effects of a natural hormone that helps regulate appetite and blood sugar after meals. Cagrilintide works in a different way by imitating amylin, another hormone involved in controlling hunger and glucose levels. Researchers believed that using both medicines together could create a stronger effect than either medicine alone.
To test this idea, scientists conducted several studies involving people with type 2 diabetes whose blood sugar levels remained above recommended targets. Some participants were taking metformin alone, while others also used SGLT2 inhibitors or insulin.
In one study, participants received either the combined treatment or placebo injections for 40 weeks. The results showed substantial improvements in HbA1c levels among those receiving the active treatment. HbA1c provides a picture of average blood sugar levels over roughly three months and is considered one of the most reliable ways to measure diabetes control.
People receiving the higher dose of the combined treatment experienced much larger reductions in HbA1c than those receiving placebo. Even the lower-dose combination produced significant improvements. These findings suggested that the treatment was helping patients gain better control over their diabetes.
The largest study involved more than 2,700 adults who were overweight or obese and whose diabetes was not adequately controlled despite treatment. Researchers compared the combined treatment against semaglutide alone, cagrilintide alone, and placebo.
The combination consistently outperformed semaglutide alone in lowering HbA1c levels. While the difference between treatments was not dramatic, it was statistically meaningful and suggests that the two medicines may complement each other.
Another study examined people already using basal insulin. These patients often represent a particularly difficult group to treat because insulin alone is not always enough to maintain healthy blood sugar levels. In these participants, the combination treatment again produced larger improvements than placebo.
The potential significance of these findings goes beyond blood sugar control. Many people with type 2 diabetes also struggle with excess weight, which worsens insulin resistance and increases the risk of heart disease. Because both semaglutide and cagrilintide influence appetite and food intake, researchers hope that the treatment may provide broader metabolic benefits.
The studies add to growing evidence that combining therapies that target different biological pathways may be one of the most effective strategies for managing type 2 diabetes. Rather than relying on a single mechanism, the combined treatment appears to attack the problem from multiple angles, helping the body regulate blood sugar more effectively.
Nevertheless, some caution is warranted. The studies followed participants for less than two years. Longer studies will be needed to determine whether the benefits remain strong over time and whether the treatment reduces major health outcomes such as heart attacks, strokes, kidney disease, and diabetes-related deaths.
It is also important for readers to understand that Novo Nordisk, the company developing cagrilintide, funded the research, and several study authors disclosed financial relationships with pharmaceutical companies. Such disclosures do not invalidate the findings, but they are important factors to consider when evaluating clinical research.
Despite these limitations, the studies provide strong evidence that the combination of cagrilintide and semaglutide could become an important new option for people whose diabetes remains difficult to manage. The fact that positive results were observed in different patient populations strengthens confidence in the treatment’s potential value.
Looking at the overall evidence, the findings are impressive because they come from multiple well-designed clinical trials involving thousands of participants. The treatment consistently improved blood sugar control across different groups of patients.
However, the true test will be whether these improvements lead to better long-term health outcomes. If future studies confirm reductions in diabetes complications and cardiovascular disease, this combination therapy could represent one of the most important advances in diabetes care in recent years.
If you care about diabetes, please read studies about 5 vitamins that may prevent complication in diabetes, and how to manage high blood pressure and diabetes with healthy foods.
For more health information, please see recent studies about vitamin D and type2 diabetes, and to people with type 2 diabetes, some fruits are better than others.
Source: Brigham and Women’s Hospital, University of North Carolina School of Medicine, and University of Texas Southwestern Medical Center.
